Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study Assessing the Safety of Anti-Fibrotic Therapy in the Peri-Transplant Period in Idiopathic Pulmonary Fibrosis Patients from Australia and New Zealand Cardiothoracic Organ Transplant Registry (ANZCOTR).

Trial Profile

A Retrospective Study Assessing the Safety of Anti-Fibrotic Therapy in the Peri-Transplant Period in Idiopathic Pulmonary Fibrosis Patients from Australia and New Zealand Cardiothoracic Organ Transplant Registry (ANZCOTR).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Apr 2018 New trial record
    • 14 Apr 2018 Preliminary results (n=43; to date) assessing anastomotic outcomes in idiopathic pulmonary fibrosis patients receiving anti-fibrotic therapy (pirfenidone and nintedanib) in the peri-transplant period, presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top